The use of ICIs in cancer immunotherapy has revolutionized the management of advanced‐stage cancers,[49] and ICIs that specifically target the programmed cell death‐1 receptor (PD‐1) have shown significant survival benefits in a subset of patients with KIRC.[50] However, the mechanisms driving resistance to PD‐1/PD‐L1 blockade are poorly understood. The gene discussed is CD274; the disease is cancer.